How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,634 results for

Squamous Cell Carcinoma of the Skin

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

13821. Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer

Hematopoietic Not specified Hepatic Not specified Renal Not specified Other Patients must use effective contraception No other malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ at any other site No major medical or psychiatric illness that would preclude study therapy No hip prosthesis PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy No prior chemotherapy Endocrine therapy Prior neoadjuvant hormonal therapy allowed provided (...) interstitial brachytherapy with external-beam radiation therapy may kill more tumor cells. It is not yet known whether interstitial brachytherapy is more effective with or without external-beam radiation therapy in treating prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of interstitial brachytherapy with or without external-beam radiation therapy in treating patients who have prostate cancer. Condition or disease Intervention/treatment Phase Prostate Cancer Radiation

2003 Clinical Trials

13822. Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer

of immune cells found in bone marrow or peripheral blood and may help a person's immune system kill more tumor cells. Condition or disease Intervention/treatment Phase Recurrent Prostate Carcinoma Stage IV Prostate Cancer AJCC v7 Biological: Ipilimumab Other: Laboratory Biomarker Analysis Other: Pharmacological Study Biological: Sargramostim Phase 1 Detailed Description: PRIMARY OBJECTIVES: I. Determine the maximum tolerated dose of anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody (...) adequately treated basal cell or squamous cell skin cancer or stage I or II cancer currently in complete remission No prior immunotherapy (e.g., vaccines or investigational) No other concurrent colony-stimulating factors No prior chemotherapy No concurrent chemotherapy See Disease Characteristics At least 4 weeks since prior systemic corticosteroids At least 4 weeks since other prior hormonal therapy, including megestrol and finasteride No concurrent systemic steroid therapy except inhaled or topical

2003 Clinical Trials

13823. 3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

No uncontrolled coronary artery disease No uncontrolled arrhythmias Pulmonary No dyspnea at rest No dependence on supplemental oxygen Other Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 3 months after study participation No other malignancy except any of the following: Carcinoma in situ of the cervix treated with cone biopsy or resection Nonmetastatic basal cell or squamous cell skin cancer Any stage I malignancy curatively resected more than (...) Information provided by: National Cancer Institute (NCI) Study Details Study Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy such as gemcitabine use different ways to stop tumor cells from dividing so they stop growing or die. 3-AP may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth and may help gemcitabine kill more cancer cells by making them more sensitive to the drug. PURPOSE: This phase II trial is studying how well giving gemcitabine

2003 Clinical Trials

13824. Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix

2018 Additional relevant MeSH terms: Layout table for MeSH terms Carcinoma Carcinoma, Squamous Cell Adenocarcinoma Uterine Cervical Neoplasms Carcinoma, Adenosquamous Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Neoplasms, Squamous Cell Uterine Neoplasms Genital Neoplasms, Female Urogenital Neoplasms Neoplasms by Site Uterine Cervical Diseases Uterine Diseases Genital Diseases, Female Neoplasms, Complex and Mixed Paclitaxel Vinorelbine Albumin-Bound Paclitaxel (...) how well they work in treating women with stage IVB, recurrent, or persistent cancer of the cervix. Drugs used in chemotherapy such as cisplatin, paclitaxel, vinorelbine, gemcitabine, and topotecan, use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen containing cisplatin is most effective in treating cervical cancer. Condition or disease Intervention/treatment Phase Cervical Adenocarcinoma Cervical

2003 Clinical Trials

13825. Hepatic Arterial Infusion With Floxuridine and Systemic Irinotecan After Surgery in Treating Patients With Hepatic (Liver) Metastases From Colorectal Cancer

potentially curative therapy for all prior malignancies No other malignancy within the past 5 years except the following: Effectively treated basal cell or squamous cell skin cancer Carcinoma in situ of the cervix that has been effectively treated by surgery alone Lobular carcinoma in situ of the ipsilateral or contralateral breast treated by surgery alone No evidence of recurrence of any prior malignancy No prior hepatic arterial infusion pump malfunction, malperfusion, or infection PRIOR CONCURRENT (...) Trials in Oncology: stage IV colon cancer adenocarcinoma of the colon adenocarcinoma of the rectum stage IV rectal cancer liver metastases Additional relevant MeSH terms: Layout table for MeSH terms Colorectal Neoplasms Neoplasm Metastasis Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases Neoplastic Processes Pathologic Processes Irinotecan

2003 Clinical Trials

13826. Fruit and Vegetable Extracts in Treating Patients With Stage I-IV, Stage IVA/IVB Head and Neck Cancer

or nursing Negative pregnancy test Fertile patients must use effective contraception No other malignancy within the past 5 years except curatively treated head and neck squamous cell carcinoma, nonmelanoma skin cancer, or carcinoma in situ of the cervix No other serious medical or psychiatric illness that would preclude giving informed consent No nausea ≥ grade 2 PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy See Disease Characteristics More than 6 months and less than 3 years (...) . To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria DISEASE CHARACTERISTICS: Curatively treated stage I-IV (including stage IVA and IVB) squamous cell carcinoma of the upper aerodigestive tract of 1 of the following primary sites: Oral

2003 Clinical Trials

13827. Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Esophagus

infection No uncontrolled diabetes mellitus (random blood sugar at least 300 mg) No peripheral neuropathy grade 2 or greater No other malignancy within the past 3 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or any other malignancy that does not carry a worse prognosis than advanced esophageal cancer No other serious underlying medical condition that would preclude study No other concurrent disease that would preclude study No psychiatric (...) Posted: June 5, 2013 Last Verified: June 2013 Keywords provided by Memorial Sloan Kettering Cancer Center: stage II esophageal cancer stage III esophageal cancer stage IV esophageal cancer squamous cell carcinoma of the esophagus adenocarcinoma of the esophagus Additional relevant MeSH terms: Layout table for MeSH terms Esophageal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Head and Neck Neoplasms Digestive System Diseases Esophageal Diseases

2002 Clinical Trials

13828. Vaccine Therapy in Treating Patients at High Risk for Breast Cancer Recurrence

except basal cell or squamous cell skin cancer PRIOR CONCURRENT THERAPY: Biologic therapy: At least 6 weeks since prior immunotherapy No prior vaccine with any of the antigens in this study Chemotherapy: See Disease Characteristics At least 4 weeks since prior chemotherapy No concurrent chemotherapy Endocrine therapy: See Disease Characteristics Radiotherapy: See Disease Characteristics At least 4 weeks since prior radiotherapy No concurrent radiotherapy Surgery: See Disease Characteristics At least (...) Keywords provided by Memorial Sloan Kettering Cancer Center: stage I breast cancer stage II breast cancer stage IV breast cancer stage IIIA breast cancer recurrent breast cancer stage IIIB breast cancer stage IIIC breast cancer male breast cancer Additional relevant MeSH terms: Layout table for MeSH terms Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Vaccines Saponin QA-21V1 Keyhole-limpet hemocyanin Immunologic Factors Physiological Effects of Drugs Adjuvants, Immunologic

2002 Clinical Trials

13829. Erlotinib and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

., fluorescein or Bengal-Rose) No abnormal corneal sensitivity test (e.g., Schirmer test or similar tear production test) Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No other malignancy within the past 5 years except carcinoma in situ of the cervix, nonmelanoma skin cancer, or second primary squamous cell cancer originating from the head and neck No grade 2 or greater residual ototoxicity or neuropathy from prior platinum-based therapy (...) Accepts Healthy Volunteers: No Criteria DISEASE CHARACTERISTICS: Histologically confirmed squamous cell carcinoma of the head and neck All primary sites, including oral cavity, oropharynx, nasopharynx, hypopharynx, larynx, and paranasal sinus Recurrent, unresectable, and/or metastatic disease At least 1 measurable lesion At least 20 mm with conventional techniques OR at least 10 mm with spiral CT scan Lesions accessible for biopsy Tumor specimen available for evaluation of epidermal growth factor

2002 Clinical Trials

13830. Liposomal Doxorubicin in Treating Patients With Persistent or Recurrent Cancer of the Cervix

Oncology Group Collaborator: National Cancer Institute (NCI) Information provided by: Gynecologic Oncology Group Study Details Study Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness liposomal doxorubicin in treating patients who have persistent or recurrent cancer of the cervix. Condition or disease Intervention/treatment Phase Cervical Cancer Drug (...) : pegylated liposomal doxorubicin hydrochloride Phase 2 Detailed Description: OBJECTIVES: Determine the antitumor activity of doxorubicin HCl liposome in patients with persistent or recurrent squamous cell carcinoma of the cervix. Determine the toxicity of this drug in these patients. OUTLINE: This is a multicenter study. Patients receive doxorubicin HCl liposome IV over 1 hour on day 1. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients are followed

2002 Clinical Trials

13831. Breast-Conserving Therapy Compared With Mastectomy Followed By Radiation Therapy in Treating Women With Locally Advanced Breast Cancer Previously Treated With Chemotherapy

count at least 100,000/mm^3 Hepatic: Bilirubin less than 1.5 times normal SGOT and SGPT no greater than 2 times normal Alkaline phosphatase no greater than 2 times normal Renal: Creatinine less than 1.5 times normal Other: No other prior or concurrent malignancy except adequately treated squamous cell or basal cell skin cancer or adequately treated cone-biopsied carcinoma in situ of the cervix No serious underlying medical illness that would preclude study No psychiatric or addictive disorder (...) information Ages Eligible for Study: Child, Adult, Older Adult Sexes Eligible for Study: Female Accepts Healthy Volunteers: No Criteria DISEASE CHARACTERISTICS: Histologically or cytologically confirmed locally advanced breast cancer T3 inoperable, N0-N2 Any T, N2 T4, N0-N2 Inflammatory breast carcinoma Prior treatment with 4-6 courses of standard induction chemotherapy or active investigational regimens completed within the past 4 weeks Residual tumor size less than 5 cm No fixed axillary lymph nodes

2002 Clinical Trials

13832. Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer

of the Stomach Male Breast Cancer Mixed Adenocarcinoma of the Stomach Ovarian Endometrioid Adenocarcinoma Paget Disease of the Breast With Intraductal Carcinoma Paget Disease of the Breast With Invasive Ductal Carcinoma Recurrent Adult Primary Liver Cancer Recurrent Breast Cancer Recurrent Colon Cancer Recurrent Gallbladder Cancer Recurrent Gastric Cancer Recurrent Malignant Testicular Germ Cell Tumor Recurrent Pancreatic Cancer Recurrent Rectal Cancer Recurrent Salivary Gland Cancer Salivary Gland (...) marrow or peripheral blood. Combining vaccine therapy with sargramostim may make tumor cells more sensitive to the vaccine and may kill more tumor cells Condition or disease Intervention/treatment Phase Adenocarcinoma of the Colon Adenocarcinoma of the Gallbladder Adenocarcinoma of the Pancreas Adenocarcinoma of the Rectum Adult Primary Hepatocellular Carcinoma Advanced Adult Primary Liver Cancer Cholangiocarcinoma of the Gallbladder Diffuse Adenocarcinoma of the Stomach Intestinal Adenocarcinoma

2002 Clinical Trials

13833. Liposomal Doxorubicin and Gemcitabine in Treating Women With Metastatic Breast Cancer

Cardiovascular: No prior cardiac disease within the past 5 years OR LVEF at least 50% Other: No prior uncontrolled seizures No uncontrolled systemic infection No anthracycline resistance No other malignancy within the past 5 years except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: No prior trastuzumab (Herceptin (...) : January 27, 2003 Last Update Posted : December 18, 2013 Sponsor: Pharmatech Oncology Information provided by: National Cancer Institute (NCI) Study Details Study Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of combining liposomal doxorubicin with gemcitabine in treating women who have metastatic breast cancer. Condition or disease Intervention

2001 Clinical Trials

13834. S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer

the past 6 months No active coronary artery disease requiring antianginal therapy No active thrombophlebitis Pulmonary: No history of pulmonary embolus Other: No other prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or adequately treated stage I or II cancer currently in complete remission PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior biologic therapy and recovered No concurrent biologic therapy Chemotherapy: No prior (...) stop the adrenal glands from producing androgens. Combining chemotherapy with hormone therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus hormone therapy in treating patients who have metastatic prostate cancer. Condition or disease Intervention/treatment Phase Prostate Cancer Drug: bicalutamide Drug: estramustine Drug: etoposide Drug: flutamide Drug: goserelin Drug: leuprolide Drug: nilutamide Drug: paclitaxel Phase 2 Detailed

2002 Clinical Trials

13835. Flavopiridol and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer That Has Not Responded to Previous Paclitaxel

provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria DISEASE CHARACTERISTICS: Histologically confirmed squamous cell carcinoma or adenocarcinoma of the esophagus or carcinoma of the gastroesophageal (GE) junction If tumor extends below the GE junction into the proximal stomach, 50% of the tumor must involve the esophagus or GE junction (...) -00060 NCI-1672 First Posted: January 27, 2003 Last Update Posted: June 24, 2013 Last Verified: April 2004 Keywords provided by National Cancer Institute (NCI): stage III esophageal cancer stage IV esophageal cancer recurrent esophageal cancer squamous cell carcinoma of the esophagus adenocarcinoma of the esophagus Additional relevant MeSH terms: Layout table for MeSH terms Esophageal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Head and Neck Neoplasms

2000 Clinical Trials

13836. Nitrocamptothecin in Treating Patients With Advanced Ovarian Cancer

, and SGPT no greater than 2.5 times ULN (no greater than 5 times ULN if hepatic metastases present) Renal: Creatinine no greater than 1.7 mg/dL Cardiovascular: No ischemic heart disease within the past 6 months Normal 12 lead electrocardiogram Other: Not pregnant or nursing Fertile patients must use effective contraception No unstable systemic disease or active uncontrolled infections No other prior or concurrent malignancy except adequately treated basal cell or squamous cell skin cancer or cone (...) by (Responsible Party): European Organisation for Research and Treatment of Cancer - EORTC Study Details Study Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have advanced ovarian cancer. Condition or disease Intervention/treatment Phase Ovarian Cancer Drug: rubitecan Phase 2 Detailed Description: OBJECTIVES

2000 Clinical Trials

13837. Gemcitabine in Treating Patients With Persistent or Recurrent Cancer of the Cervix

Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: Female Accepts Healthy Volunteers: No Criteria DISEASE CHARACTERISTICS: Diagnosis of persistent or recurrent nonsquamous cell carcinoma of the cervix that has failed local therapeutic measures and is considered incurable Eligible subtypes: Adenocarcinoma Adenosquamous carcinoma Undifferentiated carcinoma Must have documented disease progression Histologic confirmation of original primary tumor required (...) : National Cancer Institute (NCI) Information provided by: Gynecologic Oncology Group Study Details Study Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of gemcitabine in treating patients who have persistent or recurrent cancer of the cervix. Condition or disease Intervention/treatment Phase Cervical Cancer Drug: gemcitabine hydrochloride Phase 2

2000 Clinical Trials

13838. Cisplatin, Paclitaxel, and Gemcitabine in Treating Patients With Progressive Unresectable Regional or Metastatic Bladder Cancer

than 1.36 mg/dL Cardiovascular: No uncontrolled cardiac disease No severe cardiac arrhythmias Other: Not pregnant or nursing No other prior malignancy except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: Biologic therapy: Prior intravesical immunotherapy for superficial disease allowed No prior systemic biologic response modifier therapy for advanced disease Chemotherapy: Prior intravesical chemotherapy for superficial (...) : July 24, 2008 Last Verified: November 2001 Keywords provided by National Cancer Institute (NCI): stage III bladder cancer stage IV bladder cancer transitional cell carcinoma of the bladder Additional relevant MeSH terms: Layout table for MeSH terms Urinary Bladder Neoplasms Urologic Neoplasms Urogenital Neoplasms Neoplasms by Site Neoplasms Urinary Bladder Diseases Urologic Diseases Paclitaxel Albumin-Bound Paclitaxel Cisplatin Gemcitabine Antineoplastic Agents, Phytogenic Antineoplastic Agents

2000 Clinical Trials

13839. Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer

contraception No active infection No prior malignancies except adequately treated basal or squamous cell skin cancer or carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: Biologic therapy: No greater than 1 prior biologic response modifier treatment for metastatic disease Chemotherapy: No greater than 1 prior chemotherapy regimen for metastatic disease allowed Patients who relapsed during or within 6 months after adjuvant chemotherapy are considered to have failed 1 regimen Patients who relapsed more (...) 2010 Keywords provided by Case Comprehensive Cancer Center: stage IV breast cancer recurrent breast cancer Additional relevant MeSH terms: Layout table for MeSH terms Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Cisplatin Etoposide Etoposide phosphate Ifosfamide Isophosphamide mustard Mesna Antineoplastic Agents Antineoplastic Agents, Phytogenic Topoisomerase II Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action

2000 Clinical Trials

13840. Combination Chemotherapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

2,000/mm^3 Platelet count greater than 100,000/mm^3 Hemoglobin greater than 9 g/dL Hepatic: Alkaline phosphatase no greater than 2 times upper limit of normal (ULN) (unless bone metastasis) Bilirubin less than 2 times ULN Renal: Creatinine less than 2 times ULN Cardiovascular: Adequate cardiac function Other: No other prior malignancy except curatively treated basal or squamous cell skin cancer or carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy (...) : March 1, 2011 Last Verified: September 2000 Keywords provided by National Cancer Institute (NCI): adenocarcinoma of the prostate stage IV prostate cancer recurrent prostate cancer Additional relevant MeSH terms: Layout table for MeSH terms Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site Neoplasms Genital Diseases, Male Prostatic Diseases Hormones Vinorelbine Mitoxantrone Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs

2000 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>